Gene therapy in advanced metachromatic leukodystrophy: tempering expectations
2024

Gene therapy in advanced metachromatic leukodystrophy: tempering expectations

Sample size: 3 publication Evidence: low

Author Information

Author(s): Schoenmakers Daphne H, Beerepoot Shanice, Adang Laura A, Asbreuk Marije A B C, Bergner Caroline G, Bley Annette E, Boelens Jaap-Jan, Calbi Valeria, Darling Alejandra, Eklund Erik, García Cazorla Ángeles, Grønborg Sabine W, Groeschel Samuel, van Hasselt Peter M, Hollak Carla E M, Horgan Claire, Jones Simon, de Koning Tom, Laugwitz Lucia, Lindemans Caroline, Martin Pascal, Mochel Fanny, Øberg Andreas, Ram Dipak, Sevin Caroline, Schöls Ludger, Zerem Ayelet, Wolf Nicole I, Fumagalli Francesca

Primary Institution: Amsterdam UMC, Vrije Universiteit Amsterdam

Hypothesis

Can gene therapy provide clinical benefits in patients with advanced symptomatic metachromatic leukodystrophy?

Conclusion

The study's claims of improvement from gene therapy in advanced MLD patients are questionable and lack sufficient detail to assess efficacy and safety.

Supporting Evidence

  • Two of the three patients presented were already clearly affected at the time of treatment.
  • The article lacks crucial details, such as detailed inclusion criteria defining 'advanced disease status.'
  • Previous research emphasizes that severe nervous system damage is irreversible.
  • The impressive improvement from GMFC-MLD level 4 to level 0 in MLD01 is questionable.
  • Treatment before developing central nervous system symptoms is generally followed by good clinical outcomes.
  • Newborn screening is the best option to identify patients in time for successful treatment.

Takeaway

This study looked at gene therapy for a rare disease, but the results might give false hope because they don't have enough information to prove it works.

Potential Biases

The claims may foster false hope among patients and families due to significant gaps in data.

Limitations

The study lacks crucial details such as inclusion criteria for advanced disease status and the total number of treated patients.

Participant Demographics

Three patients with metachromatic leukodystrophy, two with advanced symptoms and one diagnosed pre-symptomatically.

Digital Object Identifier (DOI)

10.1093/procel/pwae065

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication